Jansitin Duo

Metformin Hydrochloride, the active ingredient in Jansitin Duo, is a biguanide/DPP-4 inhibitor presented as an oral dosage form for oral use. It treats type 2 diabetes mellitus in adults and combines metformin, which lowers hepatic glucose output, with sitagliptin, a DPP‑4 inhibitor that enhances incretin activity, providing complementary glucose control.

GNH USA supplies Jansitin Duo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin Duo, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, targeting multiple pathways to improve overall glucose regulation.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Adjunct to diet and exercise: enhances glycemic control when lifestyle measures alone are inadequate. - When metformin monotherapy is insufficient: adds DPP‑4 inhibition to achieve target HbA1c.

Jansitin Duo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Hypoglycemia: especially when combined with insulin or sulfonylureas. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before prescribing Jansitin Duo, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Lactic acidosis risk: contraindicated in patients with significant hepatic or renal disease. - Hypoglycemia monitoring: adjust doses of concomitant insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Drug interactions: review concomitant medications that may affect renal clearance or increase metformin levels. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Jansitin Duo can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Severe renal impairment: may precipitate metformin accumulation and lactic acidosis. - Strong CYP2C8 inhibitors: increase metformin plasma concentrations. - Co‑administration with insulin secretagogues: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise metformin levels. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: may increase risk of lactic acidosis in susceptible patients.